title: [A case report of the 8 year survivor--unresectable liver metastases from advanced gastric cancer (Stage IV) were completely responsive, after 4 years from a total sequential gastrectomy, combining docetaxel treatment to regress the recurrence].
abstract: This case was a 69-year-old male who had advanced gastric cancer with unresectable multiple liver metastases (Stage IV). He received a combination therapy consisting of a continuous venous infusion (cisplatin: CDDP 10 mg/body, 5-FU 500 mg/body, day 1-28). As a result, metastatic tumors in the liver completely disappeared and a total gastrectomy was sequentially performed. Four years after the surgery, neck lymph node (LN) metastases and the right adrenal metastasis appeared, and chemotherapy (TS-1, and sequentially TS-1+CDDP) was performed. But, the chemotherapy to eradicate the metastases was hardly enough to be effective. Next, docetaxel (DOC 60 mg/m2 q3w) was started. After 9 courses, they were effective and marked regressions (70%). A total of 15 courses of docetaxel administration were possible until tumor progression recurred. This regimen was not severe in toxicity for the duration except for grade 3 poor appetite. Docetaxel will be a key drug for the gastric cancer. In case of responding well to the chemotherapy, we can hope for an extended long-term survival with a continuation of this regimen.
authors.affiliation: Dept. of Surgery, Minoh City Hospital, Gastrointestinal Research Center.
authors.forename: Shohei
authors.initials: S
authors.lastname: Iijima
authors.forename: Eiji
authors.initials: E
authors.lastname: Kurokawa
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kato
authors.forename: Masaki
authors.initials: M
authors.lastname: Tsujie
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ohshima
authors.forename: Rio
authors.initials: R
authors.lastname: Handa
authors.forename: Yasuto
authors.initials: Y
authors.lastname: Naoi
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Yamamoto
authors.forename: Nobuteru
authors.initials: N
authors.lastname: Kikkawa
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D000077143:Docetaxel; D004338:Drug Combinations; D005472:Fluorouracil / Q000627:therapeutic use*; D005743:Gastrectomy; D006498:Hepatectomy; D006801:Humans; D007262:Infusions, Intravenous; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery / Q000628:therapy*; D008297:Male; D010094:Oxonic Acid / Q000008:administration & dosage; D011725:Pyridines / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000473:pathology* / Q000628:therapy*; D043823:Taxoids / Q000008:administration & dosage*; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D011725:Pyridines; D043823:Taxoids; C079198:S 1 (combination); D005641:Tegafur; D000077143:Docetaxel; D010094:Oxonic Acid; D002945:Cisplatin; D005472:Fluorouracil